"Matching" the "Mismatch" Repair-Deficient Prostate Cancer with Immunotherapy

Area of Science:

• Oncology
• Genetics
• Immunotherapy

Background:

• Mismatch repair (MMR) gene mutations are infrequent in advanced prostate cancer.
• When present, these mutations predict a strong response to immune checkpoint blockade (ICB).
• Accurate identification of patients with MMR alterations is essential for treatment selection.

Purpose of the Study:

• To highlight the importance of detecting mismatch repair gene mutations in advanced prostate cancer.
• To discuss the potential of cell-free circulating tumor DNA (cfDNA)-based sequencing for identifying patients eligible for ICB.
• To emphasize the clinical significance of molecular assays in precision oncology.

Main Methods:

• Review of current literature on mismatch repair deficiency in prostate cancer.
• Evaluation of cell-free circulating tumor DNA sequencing as a diagnostic tool.
• Discussion of the role of biomarkers in predicting response to immune checkpoint blockade.

Main Results:

• Mismatch repair gene mutations are rare but actionable in advanced prostate cancer.
• Immune checkpoint blockade demonstrates efficacy in patients with these specific genetic alterations.
• Cell-free circulating tumor DNA sequencing is a feasible approach for detecting these mutations non-invasively.

Conclusions:

• Accurate detection of mismatch repair gene mutations is critical for guiding advanced prostate cancer treatment.
• Cell-free DNA sequencing offers a promising, minimally invasive method for identifying patients who can benefit from immunotherapy.
• This approach supports the advancement of personalized medicine in prostate cancer care.